Bispecific Antibody Treatment for Diffuse Large B Cell Lymphoma, a Real-World Evidence (RWE) Study
Geoffrey Shouse(City Of Hope National Medical Center), Alexey V. Danilov(City Of Hope National Medical Center), Steven T. Rosen(Unknown), James Godfrey(City of Hope), Alex F. Herrera(City of Hope), Stephen J. Forman(City Of Hope National Medical Center), Avyakta Kallam(City Of Hope National Medical Center), Azra Borogovac(University of Oklahoma Health Sciences Center), Matthew Mei(City of Hope), Stacy Pak(City Of Hope National Medical Center), Niloufer Khan(City of Hope), Tycel Phillips(City of Hope), Lu Chen(City of Hope), Brian Lee(City Of Hope National Medical Center), Jasmine M. Zain(City Of Hope National Medical Center), John H. Baird(City Of Hope National Medical Center), Tanya Siddiqi(City Of Hope National Medical Center)
Cited by 0
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k